Biography DrSc Philippe Gannon, PhD

The Maple Brief – March 2024 – Our new Quarterly Newsletter
9 April 2024
The Maple Brief – March 2024 – Our new Quarterly Newsletter
9 April 2024

Biography DrSc Philippe Gannon, PhD

DrSc Philippe Gannon, PhD is Director of Operations at the Centre for Experimental Therapies (CTE) in the Department of Oncology at the University of Lausanne and the Centre Hospitalier Universitaire Vaudois (UNIL-CHUV).

A McGill University graduate in microbiology and immunology (1999), he completed his master’s and doctoral degrees at Université de Montréal in molecular biology and onco-immunology (2009). Supported by a grant from the Fonds de la recherche en santé du Québec, in August 2011, he completed his postdoctoral fellowship in Lausanne at the UNIL-CHUV Department of Oncology, under the supervision of Dr. Nathalie Rufer, PhD, a specialist in hematology and graduate of the University of British Columbia. It was in 2015 that Mr. Gannon joined the Center for Experimental Therapies as Process Development Manager for drug production. In 2017, he was promoted to Production Manager, and in 2020 he was appointed Director of GMP Operations at the ETC, a position he currently holds.

In addition to these scientific skills, Mr. Gannon has knowledge of intellectual property in the life sciences to support all activities relating to the transfer of technologies developed during preclinical studies.

An avid mountain enthusiast, in his spare time he can be found speeding down the ski slopes and running the trails of the Sierre-Zinal ultra trails at the top of the Alps.

Department of Oncology UNIL-CHUV

The primary goal of the Department of Oncology is to offer new treatments and care techniques. It offers patients a personalized approach, with more effective, targeted care and fewer side-effects. Recent advances in cancer research show that the future lies in individualizing treatment programs – according to a patient’s needs and according to his or her cancer.

The Department of Oncology boasts a number of world-renowned experts, including DrSc Gannon. Over the years, these experts have set up numerous state-of-the-art infrastructures and platforms, enabling the Department to improve the care of cancer patients.

With the advent of precision medicine, which uses patient-specific biological, environmental or social data, clinical studies are making it possible to offer therapeutic options to patients suffering from rarer diseases. Currently, around a hundred clinical trials are underway at the CHUV in breast cancer, brain and spinal cord, gastrointestinal, gynecology, ENT tumors, hematology, melanoma, solid tumors, thoracic and urology.